WebMarlowe is a member of the UA spin-off company FAKnostics, LLC. Furthermore, Dr. Marlowe is a research assistant professor at the UA College of Pharmacy and College of Medicine – Phoenix, where he contributes to research projects, teaching and grant writing. [email protected] 602-827-2710 Research Interests: WebEAD@HYPERBOLICHOLDINGS +41 79 835 830. CONTACT. bottom of page
Tim Marlowe, PhD The University of Arizona College of Medicine …
WebTurner, Leins & Gold, LLC is one of the fastest growing, quality-oriented certified public accounting firms in the Washington D.C. Metropolitan area. The combination of … WebFaknostics, LLC 2914 E MINNEZONA AVE Phoenix, AZ 85016-4979 United States DUNS: 081240930 HUBZone Owned: No Woman Owned: Yes Socially and Economically Disadvantaged: No Principal Investigator Name: TIMOTHY MARLOWE Phone: (602) 807-2710 Email: [email protected] Business Contact Name: JENNIFER … my west oxon
Timothy Marlowe University of Arizona Cancer Center
WebNon-catalytic FAK inhibitors as novel therapeutics for lung fibrosis. Amount: $299,905.00. PROJECT ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and fatal fibrotic lung disorder which disproportionately affects men and the elderly. Although two drugs (pirfenidon ... STTR Phase I 2024 Department of Health and Human ... WebDr. Marlowe's laboratory primarily investigates the cancer drug target focal adhesion kinase (FAK) and the mechanisms by which cancer and fibrotic disorders depend on FAK signaling for disease progression. He is chief scientific officer of biotech company FAKnostics, LLC, focused on FAK diagnostics & therapeutics. WebFAKnostics LLC is a dynamic diagnostics and pharmaceutical company. We are developing next generation drugs that inhibit tumor growth through targeting important … Pipeline - Focal Adhesion Kinase Faknostics Clinical Advisor & Phase 1 Clinical Trial Specialist. BUSINESS ADVISORS. … Partners - Focal Adhesion Kinase Faknostics We are in preclinical testing of our FAK inhibitor for the treatment of melanoma, … FAKnostics efforts to develop a FAK inhibitor for use in NRAS-mutant … fak is one of the most ubiquitous cancer proteins found to date, with expression … Smith CS, Golubovskaya VM, Peck E, Xu L-H, Monia BP, Yang, X, Cance WG. … We are a University of Arizona spin-off company with a presence in the Phoenix … 2024 Formation of FAKnostics Biologics LLC, our affiliated entity focused on the … my west scotland